Question 1

What is CONCIZUMAB used for?

Accepted Answer

CONCIZUMAB (brand name Alhemo) is a Other indicated for See full prescribing information.

Question 2

How does CONCIZUMAB work?

Accepted Answer

CONCIZUMAB works through the following mechanism: 12.1 Mechanism of Action Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B regardless of their inhibitor status. The effect of concizumab-mtci is not influenced by the presence of inhibitory antibodies to FVIII or FIX. There is no structural relationship or sequence homology between concizumab-mtci and FVIII or FIX and, as such, treatment with concizumab-mtci does not induce or enhance the development of direct inhibitors to FVIII or FIX..

Question 3

What are the most common side effects of CONCIZUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for CONCIZUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is CONCIZUMAB the same as Alhemo?

Accepted Answer

Alhemo is a brand name for CONCIZUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

CONCIZUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations